Clinical Trial Finder

Inclusion Criteria:

• - Males and females ≥18 years of age at the time of consent.

• - Written informed consent in accordance with federal, local, and institutional guidelines.

• - Have an ECOG performance status of 0 or 1.

• - Documented diagnosis of MM per IMWG diagnostic criteria.

• - Received at least three prior MM treatment lines of therapy.

• - Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.

• - Have documented evidence of progressive disease by the IMWG criteria.

• - Subjects must have measurable disease at screening.

• - Adequate bone marrow and organ function.

Exclusion Criteria:

• - Diagnosed or treated for invasive malignancy other than multiple myeloma, except: - Malignancy treated with curative intent and with no known active disease present for ≥2 years before enrollment; or.

• - Adequately treated non-melanoma skin cancer without evidence of disease.

• - The following cardiac conditions: - New York Heart Association (NYHA) stage III or IV congestive heart failure.

• - Myocardial infarction or coronary artery bypass graft (CABG) ≤6 months prior to enrollment.

• - History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration.

• - History of severe non-ischemic cardiomyopathy.

• - Received either of the following: - An allogenic stem cell transplant within 6 months before apheresis.

Subjects who received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease (GVHD).

• - An autologous stem cell transplant ≤12 weeks before apheresis.

• - Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.

• - Plasma cell leukemia at the time of screening (>2.0×109 /L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary AL amyloidosis.

For Phase Ib It aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, immunogenicity in subjects with relapsed/ refractory Multiple Myeloma, and determine the recommended Phase 2 dose of GC012F. For Phase 2, it aims to evaluate the efficacy, pharmacokinetic characteristics, pharmacodynamic effect, and immunogenicity, changes from baseline for subject-reported health-related quality of life, overall health status in subjects with relapsed/ refractory Multiple Myeloma.

Arms

Experimental: GC012F

GC012F will be administrated in one infusion

Interventions

Biological: - GC012F

GC012F is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.